Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal CancerRaymond Wadlow, M.D.
American Society of Clinical Oncology Position Statement: Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority PopulationsNeelima Denduluri, M.D.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.Neelima Denduluri, M.D.
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.Neelima Denduluri, M.D.
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.Neelima Denduluri, M.D.
Nondiscrimination and Accessibility Requirements Notice
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.Anne M. Favret, M.D.
Innovations in American Society of Clinical Oncology Practice Guideline Development.Neelima Denduluri, M.D.
Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary.Neelima Denduluri, M.D.
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.Neelima Denduluri, M.D.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.Felasfa M. Wodajo, M.D.
Challenges With Research Contract Negotiations in Community-Based Cancer Research.
ReCAP: Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialAlex Spira, M.D., PhD, F.A.C.P.
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.Mitul Gandhi, M.D.
Importance of pharmacokinetic studies in the management of acquired factor X deficiencyTimothy A. McCarthy, M.D.
Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology PracticesAnne M. Favret, M.D., Neelima Denduluri, M.D.
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.John Feigert, M.D.
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical TrialAlex Spira, M.D., PhD, F.A.C.P.
Are Complications Associated With the Repiphysis® Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use?Felasfa M. Wodajo, M.D.
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Top Five Lesions That Do Not Need Referral to Orthopedic Oncology.Felasfa M. Wodajo, M.D.
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinomaRaymond Wadlow, M.D.
Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group.
Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
What is the effect of advanced age and comorbidity on postoperative morbidity and mortality after musculoskeletal tumor surgery?Felasfa M. Wodajo, M.D.
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinomaRaymond Wadlow, M.D.
Coginitive Impairments in Older Breast Cancer Patients Prior to Systemic Therapy: Is There an Interaction between Cancer and ComorbidityNeelima Denduluri, M.D.
A Pilot Phase I/II Personalized Therapy Trial For Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping For Stratifying Patients To Therapy With Imatinib And PanitumumabAlex Spira, M.D., PhD, F.A.C.P.
Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverseMitul Gandhi, M.D.
Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.Mitul Gandhi, M.D.
Hemophagocytic lymphohistiocytosis and disseminated histoplasmosisAlina M. Huang, M.D.
Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.Mitul Gandhi, M.D.
Mutational analysis and clinical correlation of metastatic colorectal cancer.Raymond Wadlow, M.D.
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapyDipti Patel-Donnelly, M.D.
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.Alex Spira, M.D., PhD, F.A.C.P.
An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.Alex Spira, M.D., PhD, F.A.C.P.
Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?Neelima Denduluri, M.D.
Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)Mitul Gandhi, M.D.
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumorsJacob A. Ninan, M.D.
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial.Alex Spira, M.D., PhD, F.A.C.P.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 studyAnne M. Favret, M.D.
Bridging to Survivorship in Breast Cancer-How BMI Weighs In?Neelima Denduluri, M.D.
Bridging to survivorship in breast cancer: learning how treatment impacts mental health among early stage breast cancer survivors.Neelima Denduluri, M.D.
A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer.
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.Alex Spira, M.D., PhD, F.A.C.P.
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Raymond Wadlow, M.D.
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).Dipti Patel-Donnelly, M.D.
A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.Raymond Wadlow, M.D.
Antiangiogenic therapies for advanced hepatocellular carcinomaKeeran R. Sampat, M.D.
Expert Insight: Lapatinib Tested as Adjuvant Therapy in HER2+ Breast CancerNeelima Denduluri, M.D.
Expert Insight: Genomic Variants Used To Further Stratify Risk in Breast CancerAnne M. Favret, M.D.
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation TrialAlex Spira, M.D., PhD, F.A.C.P.
Pleural effusions in patients with acute leukemia and myelodysplastic syndromeKeeran R. Sampat, M.D.
Association of implantable defibrillator therapy risk with body mass index in systolic heart failureMitul Gandhi, M.D.
Expert Insight: Adjuvant Therapy Fails for High-Risk Soft Tissue SarcomaAlex Spira, M.D., PhD, F.A.C.P.
Brentuximab Vedotin in Patients with Relapsed HIV-Related LymphomaMitul Gandhi, M.D.
Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter studyNeelima Denduluri, M.D.
A Structured Genetic Risk Evaluation and Testing Program in the Community Oncology Practice Increases Identification of Individuals at Risk for BRCA Mutations.Neelima Denduluri, M.D.
Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early Breast Cancer in the Community Setting.Neelima Denduluri, M.D.
A Phase 1/2 Study of Carlfilzomib as a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen.Dipti Patel-Donnelly, M.D.
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Dipti Patel-Donnelly, M.D.
Risk of acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy for early breast cancer in the community setting.Neelima Denduluri, M.D.
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancerRaymond Wadlow, M.D.
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome.John Feigert, M.D.
Phase II study of two eribulin regimens in combination with erlotinib in patients (pts) with previously treated advanced non-small cell lung cancerAlex Spira, M.D., PhD, F.A.C.P.
Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancerNeelima Denduluri, M.D.
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior ChemotherapyAlex Spira, M.D., PhD, F.A.C.P.
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzuma
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapyRaymond Wadlow, M.D.
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Clinical trial design in the age of molecular profiling.Alex Spira, M.D., PhD, F.A.C.P.
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.Raymond Wadlow, M.D.
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 StudyDipti Patel-Donnelly, M.D.
Concordance between the 21-gene recurrence score (RS) and the 70-gene profile (MP) in breast cancer (BC) patients (pts)Neelima Denduluri, M.D.
A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.Alex Spira, M.D., PhD, F.A.C.P.
Ixabepilone: Clinical Role in Metastatic Breast CancerNeelima Denduluri, M.D.
Phase II Study of Single-Agent Volasertib (BI 6727) for Second-Line Treatment of Urothelial Cancer (UC).Alex Spira, M.D., PhD, F.A.C.P.
Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patientsAlex Spira, M.D., PhD, F.A.C.P.
Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma; results of a randomized phase II study.Alex Spira, M.D., PhD, F.A.C.P.
Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).Alex Spira, M.D., PhD, F.A.C.P.
Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.Alex Spira, M.D., PhD, F.A.C.P.
Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.Alex Spira, M.D., PhD, F.A.C.P.
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?Keeran R. Sampat, M.D.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial
Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative Locally-Recurrent or Metastatic Breast Cancer
Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Whole Gene Expression Profiling in Ankylosing Spondylitis Shows Upregulation of Toll-Like Receptor 4 and 5Keeran R. Sampat, M.D.
Alteration of Topoisomerase II-Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline-Based Chemotherapy
Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma.Alex Spira, M.D., PhD, F.A.C.P.
Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer.Alex Spira, M.D., PhD, F.A.C.P.
Estimate of current hospice and palliative medicine physician workforce shortage.Loren Friedman, M.D., F.A.A.H.P.M.
The role of targeted agents in preoperative chemoradiation for rectal cancerRaymond Wadlow, M.D.
Direct-to-consumer advertising by companies: not ready for prime time – and maybe never.Patricia Rodriguez, M.D.